Top Abstract Purchase Related
Home
>
Node
>
Subnode

Control of low-dose heparin therapy using photometry to detect biologically active heparin

Zimmermann, R.E.; Schwering, H.; Wittrin, G.; Hollenders, T.

Der Chirurg; Zeitschrift für Alle Gebiete der Operativen Medizen 52(5): 316-319

1981

ISSN/ISBN: 0009-4722
PMID: 7238175
Document Number: 169512
The low-dose heparin prophylaxis depends upon a low-level activation of antithrombin III to prevent thrombin generation. For the routine regiment, the application of 5000 units twice daily seems sufficient to reduce fatal lung embolism. By comparing three commercially available heparins (Thrombophob, Thrombo-Vetren, Heparin-Dihydergot) the effectiveness of the so-called low-dose heparin application was controlled with a chromogenic substrate assay (Coatest, Kabivitrum). Only twice-daily Heparin-Dihydergot resulted in an average heparin level of 0.12 +/- 0.78 m/ml plasma, which was sufficient to provide an effective thrombosis prophylaxis.

Document emailed within 1 workday
Secure & encrypted payments

Levy, S.W.; Jaques, L.B. 1978: Appearance of heparin antithrombin-active chains in vivo after injection of commercial heparin and in anaphylaxis Thrombosis Research 13(3): 429-441
Suehiro, S.; Shibata, T.; Sasaki, Y.; Hattori, K.; Kumano, H.; Hosono, M.; Kinoshita, H. 1999: Use of heparin-coated cardiopulmonary bypass circuit with low-dose heparin reduces postoperative bleeding Annals of Thoracic and Cardiovascular Surgery: Official Journal of the Association of Thoracic and Cardiovascular Surgeons of Asia 5(4): 225-229
Gärdlund, B. 1996: Randomised, controlled trial of low-dose heparin for prevention of fatal pulmonary embolism in patients with infectious diseases. The Heparin Prophylaxis Study Group Lancet 347(9012): 1357-1361
White, M.M.; Siders, L.; Jennings, L.K.; White, F.L. 1992: The effect of residual heparin on the interpretation of heparin-induced platelet aggregation in the diagnosis of heparin-associated thrombocytopenia Thrombosis and Haemostasis 68(1): 88
Nakagawa, M. 1993: Heparin, low molecular weight heparin, heparinoid, and antithrombin IIi therapy of disseminated intravascular coagulation Nihon Rinsho. Japanese Journal of Clinical Medicine 51(1): 87-92
Heine, H. 1983: Transcutaneous heparin therapy. Experimental histological studies with the effective combination heparin--allantoin--D panthenol Die Medizinische Welt 34(20): 602-604
Jiménez, R.; Atmetlla, F. 1975: Comparison of methods for the control of therapy with heparin Boletin Medico del Hospital Infantil de Mexico 32(5): 977-983
Wettendorff, P.; Leotaud, P.; Martin, T.; Rodzynek, J.J. 1982: Limitation of Howell time in the control of heparin therapy Acta Clinica Belgica 37(3): 185-186
Akl, B.F.; Vargas, G.M.; Neal, J.; Robillard, J.; Kelly, P. 1980: Clinical experience with the activated clotting time for the control of heparin and protamine therapy during cardiopulmonary bypass Journal of Thoracic and Cardiovascular Surgery 79(1): 97-102
Eriksson, E.; Wollter, I.M.; Christenson, B.; Stigendal, L.; Risberg, B. 1988: Heparin and fibrinolysis--comparison of subcutaneous administration of unfractionated and low molecular weight heparin Thrombosis and Haemostasis 59(2): 284-288
Izban, K.F.; Lietz, H.W.; Hoppensteadt, D.A.; Jeske, W.P.; Fareed, J.; Bakhos, M.; Walenga, J.M. 1999: Comparison of two PF4/heparin ELISA assays for the laboratory diagnosis of heparin-induced thrombocytopenia Seminars in Thrombosis and Hemostasis 25(Suppl 1): 51-56
Bannon, P.G.; Kim, M.J.; Dean, R.T.; Dawes, J. 1995: Augmentation of vascular endothelial barrier function by heparin and low molecular weight heparin Thrombosis and Haemostasis 73(4): 706-712
Sampol, J.; Rossi, J.M.; Lejay, G. 1984: Automatization of heparin determination using chronometric evaluation of anti-Xa activity of the AT III-heparin complex Annales de Biologie Clinique 42(1): 21-23
Melissari, E.; Thye, C.; Scully, M.F.; Kakkar, V.V. 1989: Influence of whole blood on standard curve for heparin measurement--possible heparin binding by red cells Thrombosis and Haemostasis 61(2): 262-265
Uzan, A.; Marin, J.; Mardiguian, J.; Trillou, M.; Kiosseff, T.; Rougeot, C. 1987: Comparative pharmacokinetic study, in the dog, of low molecular weight heparin and standard heparin by labelling with 35S Annales Pharmaceutiques Francaises 45(6): 429-437
Kruse-Blinkenberg, H.O.; Gormsen, J. 1976: Heparin concentration in blood pre- and postoperatively in surgical patients with low dosage heparin prophylaxis Ugeskrift for Laeger 138(12): 745-747
Kudriashov, B.A.; Liapina, L.A.; Molchanova, L.V.; Rustamova, B.A. 1970: Nature of lytic effect of fibrinogen-heparin and thyroxine-heparin complexes on fibrin Voprosy Meditsinskoi Khimii 16(2): 161-168
Huisse, M.G.; Huet, Y.; Zygelman, M.; Guillin, M.C. 1983: Thrombopenia induced by standard heparin. Therapeutic attempt using a low molecular weight heparin Presse Medicale 12(10): 643
Godoy, I.; Herrera, C.; Zapata, C.; Kunstmann, S.; Abufhele, A.; Corbalán, R. 1998: Comparison of low-molecular-weight heparin and unfractionated heparin in the treatment of unstable angina Revista Medica de Chile 126(3): 259-264
Lagasse, J.P.; Bahallah, M.L.; Salem, N.; Debillon, G.; Labarrière, D.; Serve, M.P.; Advenier, V.; Causse, X.; Legoux, J.L. 1997: Acute thrombosis of the portal system. Treatment with alteplase and heparin or with heparin alone in 10 patients Gastroenterologie Clinique et Biologique 21(12): 919-923